Dxcover Launches US Operations to Commercialize Its AI-Powered Multiomic Cancer Detection Test

• Opens U.S. headquarters in Nashville – a leading healthcare and life sciences hub
• Building the foundation for clinical collaborations and commercialization

NASHVILLE, Tenn.–(BUSINESS WIRE)–#Dxcover–Dxcover, a UK-based company improving early cancer detection with its AI-powered multiomic technology, announced today the launch of its United States headquarters in Nashville, Tennessee. The move reflects Dxcover’s commitment to commercializing its PANAROMIC™ cancer test in the world’s biggest life sciences market.

Dxcover’s innovative Drop. Dry. Detect. ™ approach offers a cost-effective, high-throughput, non-invasive cancer screening platform. The new facilities will allow the company to forge partnerships with local biotech and healthcare organizations, advance local manufacturing of its innovative infrared spectroscopy platform and serve as a research and development hub aimed at extending Dxcover’s leadership in cancer diagnostics innovation.

Matthew J. Baker, Ph.D., CEO and Co-founder of Dxcover said: “The launch of our U.S. headquarters in Nashville represents a major value-building milestone for Dxcover as we accelerate our mission to make early cancer detection accessible everywhere.

“Nashville is well known for its dynamic business environment in the healthcare field and we look forward to collaborating with research institutes, health organizations, and biotech start-ups to promote precision medicine and enhance early cancer detection solution access. Organizations such as Life Science Tennessee and BioTN are vital to the enhancement of life sciences innovation, and Dxcover is eager to be an active member of this growing collective.”

Dxcover’s PANAROMIC™ technology is transforming cancer screening through a multiomic approach through infrared spectroscopy and AI-driven spectral analysis. Unlike genetic-marker-based tests, Dxcover’s platform captures the complete biological signature from a tiny blood sample, enabling earlier diagnosis and better patient outcomes. The technology is scalable and already demonstrated proof-of-concept in various forms of cancer, including brain, colorectal, lung, and pancreatic cancers. Dxcover aims to bring high-tech diagnostics to underserved populations, enhancing global healthcare equity.

About Dxcover Limited

Dxcover’s proprietary PANAROMIC™ Platform shines light on the difficulty of early cancer diagnosis. By utilizing a multiomic spectral analysis (MOSA-Dx™) approach to detect cancer, the platform can detect the presence of disease with minute volumes of liquid sample, with a turnaround time of one day. This technology goes beyond other liquid biopsy methods by harnessing the power of AI to capture the promise of the multiome, allowing early-stage detection of a range of solid tumors. Dxcover’s unique AI algorithms are built on data; over 9000 patients and 250,000 spectra ensure robust diagnostic performance that can be tuned for high sensitivity or specificity. The test result is designed to be a valuable tool for clinicians to make rapid and appropriate patient management decisions. Dxcover’s proprietary technology is patented globally.

Dxcover’s HQ is in Glasgow, UK, with their USA HQ located in Nashville, Tennessee.

Dxcover’s vision is to be the world leader in liquid biopsy and artificial intelligence in the early detection of cancer for better survival and quality of life. The mission is to deploy the Dxcover Platform for the triage of high-mortality and hard to diagnose cancers in high-risk populations, enabling access to value-based cancer care.

For further information https://www.dxcover.com/science

Contacts

Media Contact
Julian Tyndale-Biscoe

Finn Partners

[email protected]
(+44) 020 7046 8280